Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells

Purpose: This study is aimed at investigating antineoplastic efficacy of histone deacetylase inhibitor (HDACI) LBH589 on renal cell carcinoma (RCC) and elucidating the novel molecular mechanisms involved in growth arrest and apoptosis by targeting the important nonhistone molecules. Experimental Design: We analyzed the growth-inhibitory effect of LBH589 on RCC by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay in vitro and antitumor efficacy by xenograft experiments in vivo. To verify the associated molecular mechanisms involved in LBH589-mediated cell death and cell cycle progression by Western blotting and fluorescence-activated cell sorting analysis. Results: HDACI LBH589 induced degradation of both Aurora A and B kinases through a proteasome-mediated pathway by targeting HDAC3 and HDAC6. The dual degradation of Aurora A and B kinases mediated by LBH589 resulted in inducing G2-M arrest and apoptosis of renal cancer cell lines and our results also showed that LBH589 potently inhibited renal cancer cell growth in vitro and suppressed tumor formation in vivo. The Aurora A and B kinases and HDAC3 are overexpressed in the human RCC tumor tissues examined, which make them perfect targets for HDACI LBH589 treatment. Conclusions: Our in vitro and in vivo data showed that LBH589 has potent anticancer effect of renal cancer cells. LBH589 and other HDACI treatment resulted in inducing G2-M arrest and apoptosis of renal cancer cells through degradation of Aurora A and B kinases by inhibition of HDAC3 and HDAC6. The clinical efficacy of LBH589 in the treatment of patients with metastatic RCC, especially those with high Aurora kinase and HDAC expression, is worthy of further investigation.

[1]  H. Miyake,et al.  Significance of Aurora-A expression in renal cell carcinoma. , 2007, Urologic oncology.

[2]  M. Loda,et al.  The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. , 2006, Cancer research.

[3]  S. Spicer,et al.  Tissue culture of human kidney epithelial cells of proximal tubule origin. , 1984, Kidney international.

[4]  C. Korch,et al.  Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma , 2005, British Journal of Cancer.

[5]  H. Katayama,et al.  Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. , 1998, Cancer research.

[6]  Richard R. Adams,et al.  Essential Roles of Drosophila Inner Centromere Protein (Incenp) and Aurora B in Histone H3 Phosphorylation, Metaphase Chromosome Alignment, Kinetochore Disjunction, and Chromosome Segregation , 2001, The Journal of cell biology.

[7]  G. Schwartz,et al.  Aurora Kinases: New Targets for Cancer Therapy , 2006, Clinical Cancer Research.

[8]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[9]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[10]  P. Atadja,et al.  Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. , 2003, Molecular cancer therapeutics.

[11]  D. Glover,et al.  Drosophila Aurora B Kinase Is Required for Histone H3 Phosphorylation and Condensin Recruitment during Chromosome Condensation and to Organize the Central Spindle during Cytokinesis , 2001, The Journal of cell biology.

[12]  Paola Storici,et al.  PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer , 2007, Molecular Cancer Therapeutics.

[13]  L. Neckers,et al.  Modulation of p 53 , ErbB 1 , ErbB 2 , and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR 901228 , 2002 .

[14]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[15]  G. Almouzni,et al.  Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases , 2001, Nature Cell Biology.

[16]  P. Meltzer,et al.  Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[18]  B. Garcia,et al.  A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. , 2006, Genes & development.

[19]  J. Inazawa,et al.  Differentially Regulated Genes as Putative Targets of Amplifications at 20q in Ovarian Cancers , 2002, Japanese journal of cancer research : Gann.

[20]  S. Bates,et al.  Inhibitors of Histone Deacetylases Alter Kinetochore Assembly by Disrupting Pericentromeric Heterochromatin , 2005, Cell cycle.

[21]  Haiyong Han,et al.  The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. , 2004, Molecular cancer therapeutics.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[23]  Jung-Hyun Park,et al.  Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase , 2007, Journal of Molecular Medicine.

[24]  L. Neckers,et al.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.

[25]  R. Figlin,et al.  Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. , 2003, The Urologic clinics of North America.

[26]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[27]  Chuanmao Zhang,et al.  Small-molecule inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells. , 2008, Biochemical pharmacology.

[28]  H. Saya,et al.  Aurora-A — A guardian of poles , 2005, Nature Reviews Cancer.

[29]  W. Earnshaw,et al.  Chromosomal passengers and the (aurora) ABCs of mitosis. , 2001, Trends in cell biology.

[30]  T. Beckers,et al.  Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group , 2007, International journal of cancer.

[31]  Jian Kuang,et al.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.

[32]  P. Chieffi,et al.  Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation , 2006, The Prostate.

[33]  H. Katayama,et al.  Mitotic kinase expression and colorectal cancer progression. , 1999, Journal of the National Cancer Institute.

[34]  H. Katayama,et al.  Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. , 2002, Cancer research.

[35]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[36]  A. Ree,et al.  Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death , 2005, Molecular Cancer Therapeutics.

[37]  W. Earnshaw,et al.  The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.

[38]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[39]  Zu-Wen Sun,et al.  Mitotic Phosphorylation of Histone H3 Is Governed by Ipl1/aurora Kinase and Glc7/PP1 Phosphatase in Budding Yeast and Nematodes , 2000, Cell.

[40]  Wei Chen,et al.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase , 2007, Proceedings of the National Academy of Sciences.

[41]  Chung F. Wong,et al.  Exploiting novel cell cycle targets in the development of anticancer agents. , 2005, Current cancer drug targets.

[42]  Brian Schryver,et al.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.

[43]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[44]  Rajesh Odedra,et al.  AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.

[45]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[46]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[47]  H. Koeffler,et al.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. , 2007, Blood.

[48]  David Horn,et al.  Histone deacetylases. , 2008, Advances in experimental medicine and biology.